Financial Enhancement Group LLC Takes $6.67 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Financial Enhancement Group LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 18,616 shares of the biotechnology company’s stock, valued at approximately $6,671,000. United Therapeutics makes up 1.2% of Financial Enhancement Group LLC’s portfolio, making the stock its 27th biggest holding.

A number of other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC raised its holdings in United Therapeutics by 176.2% in the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after acquiring an additional 9,133 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after purchasing an additional 4,100 shares during the last quarter. Comerica Bank grew its stake in shares of United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after buying an additional 9,244 shares during the period. Tri Locum Partners LP acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $15,959,000. Finally, QRG Capital Management Inc. lifted its holdings in United Therapeutics by 12.4% in the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after acquiring an additional 1,692 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Up 3.8 %

Shares of United Therapeutics stock opened at $397.49 on Thursday. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $399.23. The company has a 50 day moving average of $357.42 and a 200 day moving average of $320.37. The company has a market capitalization of $17.75 billion, a P/E ratio of 17.46, a P/E/G ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the previous year, the firm posted $5.38 earnings per share. The company’s revenue was up 22.9% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Co. will post 25.57 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares in the company, valued at $1,384,115.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Michael Benkowitz sold 14,700 shares of United Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $964,983.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christopher Causey sold 510 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,422 shares of company stock worth $29,229,828. 11.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on UTHR. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. HC Wainwright increased their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group upped their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. LADENBURG THALM/SH SH boosted their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Argus raised their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.